Valuation: Morepen Laboratories Limited

Market Cap 65.1B 678M 599M 566M 514M 963M 973M 6.8B 2.62B 33.24B 2.55B 2.49B 107B P/E 2025
21.8x
P/E 2026 19.5x
Enterprise Value 66.63B 694M 613M 580M 526M 986M 996M 6.96B 2.68B 34.03B 2.61B 2.55B 109B EV / Sales 2025
1.45x
EV / Sales 2026 1.11x
Free-Float
57.31%
Yield 2025
0.42%
Yield 2026 0.59%
1 day-1.49%
1 week-2.90%
Current month+10.91%
1 month+11.85%
3 months+123.56%
6 months+228.81%
Current year+189.26%
1 week 115.95
Extreme 115.95
126.1
1 month 97
Extreme 97
126.9
Current year 33.44
Extreme 33.44
126.9
1 year 33.44
Extreme 33.44
126.9
3 years 31.31
Extreme 31.31
126.9
5 years 23.65
Extreme 23.65
126.9
10 years 7.21
Extreme 7.21
126.9
Manager TitleAgeSince
Chief Executive Officer 58 01/07/2026
Chief Executive Officer 62 01/02/1992
Director of Finance/CFO 59 03/04/2002
Director TitleAgeSince
Chairman 62 01/02/1992
Director/Board Member 58 13/08/2019
Director/Board Member - 22/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.49%-2.90%+143.09%+227.00% 688M
-0.01%+1.69%+63.50%+117.58% 1,056B
-1.61%-0.71%+48.89%+70.56% 655B
-1.12%-0.45%+19.35%+72.93% 471B
-1.72%-4.25%+37.79%+39.89% 342B
-0.40%+4.12%+22.89%+29.04% 277B
-0.51%-1.05%+12.98%+12.92% 257B
+1.32%+7.75%+55.19%+56.43% 226B
-0.61%+0.48%+34.95%+100.58% 189B
-0.24%-3.21%-27.79%-61.37% 170B
Average -0.55%+0.32%+41.08%+66.56% 364.36B
Weighted average by Cap. -0.45%+0.76%+39.87%+68.95%

Financials

2025 2026
Net sales 18.12B 189M 167M 158M 143M 268M 271M 1.89B 729M 9.25B 709M 693M 29.77B 18.06B 188M 166M 157M 142M 267M 270M 1.88B 726M 9.22B 707M 691M 29.67B
Net income 1.18B 12.3M 10.85M 10.27M 9.31M 17.46M 17.63M 123M 47.48M 603M 46.18M 45.18M 1.94B 949M 9.89M 8.73M 8.26M 7.49M 14.04M 14.18M 99.04M 38.17M 484M 37.13M 36.32M 1.56B
Net Debt -928K -9.67K -8.53K -8.08K -7.32K -13.73K -13.87K -96.87K -37.34K -474K -36.31K -35.52K -1.52M 1.54B 16.03M 14.14M 13.38M 12.14M 22.75M 22.98M 161M 61.87M 785M 60.18M 58.87M 2.53B
Logo Morepen Laboratories Limited
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Employees
1,919
Date Price Change Volume
29/09/26 INR 118.80 -1.49% 738,907
28/09/26 INR 120.60 +0.12% 1,421,271
25/09/26 INR 120.45 +3.26% 724,153
24/09/26 INR 116.65 -4.66% 792,678
23/09/26 INR 122.35 +2.86% 586,598
  1. Stock Market
  2. Stocks
  3. MOREPENLAB Stock